Melissa Guerdan - Smith Nephew Chief Quality and Regulatory Affairs Officer
| SNN Stock | USD 25.71 0.41 1.62% |
Executive
Ms. Melissa Guerdan is Chief Quality and Regulatory Affairs Officer of the Company. She joined Smith Nephew in July 2018 with responsibility for Quality and Regulatory Affairs and is based in Andover, US. Skills and Experience Melissa brings more than 20 years of leadership experience in Quality and Regulatory Affairs spanning the pharmaceutical, medical device and biologics industries. Melissa has deep compliance and operations knowledge and has progressed through senior leadership roles in global organisations including Pfizer, Baxter, Covidien and Alere. Most recently, Melissa was Senior Vice President, Quality and Regulatory for Alere where she had executive responsibility for establishing enterprise vision, strategy and direction for all aspects of quality, compliance and regulatory affairs. Melissa is adept at inspiring diverse global organisations to achieve common goals and has consistently delivered material value at the enterprise level through transformational quality and regulatory improvement programmes. Melissa holds a BA degree in Biology and Psychology, and holds an MBA from DePaul University. since 2018.
| Age | 45 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | Building 5, Watford, United Kingdom, WD18 8YE |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has Return on Asset of 0.0451 % which means that on every $100 spent on assets, it made $0.0451 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0584 %, implying that it generated $0.0584 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to 0.04. In addition to that, Return On Capital Employed is likely to drop to 0.05. At this time, Smith Nephew's Intangibles To Total Assets are very stable compared to the past year. As of the 29th of November 2024, Asset Turnover is likely to grow to 0.94, while Intangible Assets are likely to drop about 817 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brent JD | Bruker | 49 | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Stephen Deitsch | Paragon 28 | 52 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Jane Rady | Glaukos Corp | 76 | |
| Andrew Hill | Paragon 28 | 40 | |
| Eric Dasso | Alphatec Holdings | 51 | |
| Hans Kestler | Paragon 28 | N/A | |
| Justin Ward | Bruker | N/A | |
| Brian Kearns | Globus Medical | 57 | |
| Matthew Brinckman | Paragon 28 | N/A | |
| Chris Calcaterra | Glaukos Corp | 64 | |
| Daniel Esq | CONMED | 60 | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| Douglas Devine | iRhythm Technologies | 54 | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Deanna Wilke | LivaNova PLC | N/A | |
| Frank Vizesi | Orthofix Medical | N/A | |
| MD FACS | Glaukos Corp | N/A | |
| Richard Glaze | CONMED | 58 | |
| Ahmet Tezel | LivaNova PLC | N/A | |
Management Performance
| Return On Equity | 0.0584 | ||||
| Return On Asset | 0.0451 |
Smith Nephew SNATS Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bob White, Non-Executive Independent Director | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Independent Director | ||
| Deepak Nath, Chief Executive Officer | ||
| Marc Owen, Non-Executive Independent Director | ||
| AnneFrancoise Nesmes, Chief Financial Officer, Executive Director | ||
| Helen Barraclough, Company Counsel | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, President Orthopaedics | ||
| Roland Diggelmann, Chief Executive Officer, Executive Director | ||
| Vinita Bali, Non-Executive Independent Director | ||
| Simon Fraser, President - Advanced Wound Management and Global Commercial Operations | ||
| John Rogers, CFO Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Ian Melling, Interim Chief Financial Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, Senior Communications | ||
| Katarzyna MazurHofsaess, Non-Executive Independent Director | ||
| Rick Medlock, Non-Executive Independent Director | ||
| Peter Coenen, President - EMEA Region | ||
| Robin Freestone, Senior Non-Executive Independent Director | ||
| Paul Connolly, President Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Independent Director | ||
| Myra Eskes, President - Asia Pacific | ||
| Mark Gladwell, President - Global Operations and Global Business Services | ||
| John Ma, Non-Executive Independent Director | ||
| Andrew Swift, Vice Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Steve Kane, Global US | ||
| Brad Cannon, President - Sports Medicine & ENT | ||
| Jo Hallas, Non-Executive Director | ||
| Catheryn ORourke, Chief Legal and Compliance Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0584 | ||||
| Return On Asset | 0.0451 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 14 B | ||||
| Shares Outstanding | 435.99 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 7.86 % | ||||
| Number Of Shares Shorted | 3.12 M | ||||
| Price To Earning | 25.42 X |
Pair Trading with Smith Nephew
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Smith Nephew position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Smith Nephew will appreciate offsetting losses from the drop in the long position's value.Moving together with Smith Stock
Moving against Smith Stock
| 0.94 | MD | Mednax Inc | PairCorr |
| 0.85 | ELMD | Electromed | PairCorr |
| 0.81 | VREX | Varex Imaging Corp | PairCorr |
| 0.79 | OM | Outset Medical | PairCorr |
| 0.78 | DOCS | Doximity Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Smith Nephew could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Smith Nephew when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Smith Nephew - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Smith Nephew SNATS to buy it.
The correlation of Smith Nephew is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Smith Nephew moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Smith Nephew SNATS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Smith Nephew can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.244 | Dividend Share 0.375 | Earnings Share 0.7 | Revenue Per Share 2.5904 | Quarterly Revenue Growth 0.034 |
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.